Stanford-Lucidify EEG Delirium Study
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 80 people, planned
- Started
- 1 Jun 2025
- Planned end
- 30 May 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Electroencephalogram (EEG)
- Record updated
- 31 May 2025
Who can take part
- Age
- 55 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age is 55 years or older
- Clinical suspicion of delirium or subject at risk for delirium
- Admitted to the Intensive Care Unit (ICU) or Oncology wards
- Expected hospital stay is greater than one (1) day
- Subject must be fluent in English
Who cannot take part
- Subjects with a primary neurological or neurosurgical condition such as stroke, epilepsy, brain tumor, or witnessed seizures, Parkinson's disease, traumatic brain injury, or s/p craniectomy
- Age is younger than 55 years
- Active CNS substance abuse, intoxication, or withdrawal
- Unarousable or unresponsive subjects with RASS <-3
- Subject is blind, deaf, or unable to speak or understand English
Where in United States
- Stanford Hospital and ClinicsStanford, United StatesContact: Derek O Pipolo, M.D.Not yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the effectiveness of the CGX/Lucidify EEG system in enabling physicians to detect delirium (confusion) in medically ill patients as early as possible in order to minimize the detrimental effects of delirium. The study will involve collecting EEG data through the CGX EEG system (a Research-grade 2-Channel EEG device) and applying the Lucidify EEG software algorithm to identify indicators and degree of delirium, obtain data regarding the amount and degree of patient's movement and activity throughout the day in order to detail delirium subtype, and obtain data regarding the quality of the sleep as it affects delirium severity and duration. By enhancing early detection, this research aims to improve patient outcomes and inform clinical decision-making.
The 2 groups in the trial
- ICU Population
Subjects admitted to the Intensive Care Unit (ICU)
Treatment: Electroencephalogram (EEG)
- Oncology Population
Subjects admitted to oncology units with hematologic malignancies undergoing cellular therapies or hematopoietic stem cell transplants (e.g., stem cell and Chimeric Antigen Receptor T-cell (CAR-T) Therapy)
Treatment: Electroencephalogram (EEG)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Stanford-Lucidify Delirium Monitoring Pilot Study
- Record updated
- 31 May 2025